MENU
+Compare
PTCT
Stock ticker: NASDAQ
AS OF
Aug 11, 11:56 AM (EDT)
Price
$45.04
Change
-$0.34 (-0.75%)
Capitalization
3.6B

PTCT PTC Therapeutics Forecast, Technical & Fundamental Analysis

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders... Show more

Industry: #Biotechnology
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PTCT with price predictions
Aug 08, 2025

Momentum Indicator for PTCT turns positive, indicating new upward trend

PTCT saw its Momentum Indicator move above the 0 level on July 29, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PTCT's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 10-day moving average for PTCT crossed bullishly above the 50-day moving average on August 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PTCT advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where PTCT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PTCT turned negative on August 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

PTCT moved below its 50-day moving average on August 08, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PTCT broke above its upper Bollinger Band on July 31, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PTCT entered a downward trend on July 29, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PTCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (18.662). P/E Ratio (6.437) is within average values for comparable stocks, (54.033). PTCT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (2.103) is also within normal values, averaging (286.048).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PTCT is expected to report earnings to rise 22.89% to -101 cents per share on October 23

PTC Therapeutics PTCT Stock Earnings Reports
Q3'25
Est.
$-1.02
Q2'25
Beat
by $0.23
Q1'25
Beat
by $11.07
Q4'24
Missed
by $0.06
Q3'24
Beat
by $0.12
The last earnings report on August 07 showed earnings per share of -82 cents, beating the estimate of -105 cents. With 106.56K shares outstanding, the current market capitalization sits at 3.60B.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
100 Corporate Court
Phone
+1 908 222-7000
Employees
1058
Web
https://www.ptcbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSRLX78.090.83
+1.07%
Touchstone Large Cap Focused R6
CNRUX26.270.22
+0.84%
City National Rochdale US Cor Eq Instl
RPRCX8.270.06
+0.73%
Royce Premier Consult
SRFMX14.890.09
+0.61%
Sarofim Equity
MEIJX51.220.23
+0.45%
MFS Value R4

PTCT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PTCT has been loosely correlated with ACLX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PTCT jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
-9.89%
ACLX - PTCT
45%
Loosely correlated
-0.91%
SYRE - PTCT
44%
Loosely correlated
N/A
IDYA - PTCT
43%
Loosely correlated
+3.08%
BHVN - PTCT
42%
Loosely correlated
-3.22%
RXRX - PTCT
42%
Loosely correlated
-0.92%
More